Telomerase-Derived Peptide Composition for Cachexia Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cachexia, a syndrome characterized by weight loss, anemia, edema, and loss of appetite, are ineffective and associated with harmful side effects, and do not adequately address the underlying metabolic and inflammatory issues caused by chronic diseases such as cancer, AIDS, and rheumatoid arthritis.
Innovation Solution
A composition comprising a peptide derived from human telomerase, with an amino acid sequence identity of 80% or greater, is administered to prevent or treat cachexia, targeting symptoms like weight loss, anemia, and loss of appetite, and is effective in various disease conditions including AIDS, cancer, and rheumatoid arthritis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments for cachexia are administered, then nutritional supplementation is provided, but harmful side effects occur and treatment effectiveness is limited
Solution Approach 1:
The patent extracts and utilizes a specific peptide sequence (SEQ ID NO: 1) from telomerase protein as the active therapeutic component, isolating the beneficial anti-cachexia effect from the complex telomerase structure to create a targeted treatment with reduced side effects
Solution Approach 2:
The patent changes the therapeutic parameter from conventional nutritional supplements to a specific peptide sequence derived from telomerase, fundamentally altering the treatment mechanism to address cachexia through telomerase-derived peptide activity rather than nutritional supplementation
2Quantity of substance
If nutritional supplements and intravenous hyperalimentation are administered to improve cachexia, then energy and nutritional intake are increased, but treatment complexity and harmful effects increase
Solution Approach 1:
The patent extracts the essential therapeutic function from complex nutritional support systems and concentrates it into a single peptide molecule (SEQ ID NO: 1) that can be administered orally or parenterally, eliminating the need for complex intravenous hyperalimentation equipment and procedures
Solution Approach 2:
The patent employs a simple peptide composition that can be administered as a straightforward pharmaceutical formulation, replacing complex, expensive, and invasive nutritional support systems with a more accessible and simpler treatment approach
Data Source
AI summary
The present invention relates to composition for preventing or treating cachexia, and more specifically, to a composition for preventing or treating cachexia containing a peptide derived from a telomerase. The composition for preventing or treating cachexia, according to present invention, has the advantages of improving symptoms of cachexia, such as weight loss, anemia, edema, and loss of appetite, and has few side effects.